Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
U.S. Department of Defense awards $4 million to researchers at OHSU, University of Washington, VA Portland, VA Puget Sound to ...
Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...
Mitochondria are critical for cellular homeostasis, regulating bioenergetics, redox balance, Ca2+ signaling, and cell death.
Hosted on MSN4d
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
Over time, the disease can also affect memory and lead to dementia. A similar condition called Lewy Body Dementia (LBD), ...
New biomarker tests can enable early diagnosis and prompt treatment of symptoms associated with synucleinopathies, according ...
While manganese is an essential mineral involved in many bodily functions, both deficiency and excessive exposure can cause ...
While manganese is an essential mineral involved in many bodily functions, both deficiency and excessive exposure can cause ...
"Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the ...
By converting the light into heat, the tiny gold particles trigger changes in the cells that promote repair while releasing peptides that help break down and clear out the alpha-synuclein protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback